News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Working with U.S. Department of Defense, Canopus BioPharma, Inc. Announces Phase II Human Clinical Trial for Innovative Hepatitis C Drug, CB5300



11/4/2008 9:02:16 AM

LOS ANGELES--(BUSINESS WIRE)--Canopus BioPharma, Inc. (OTC:CBIA);(www.canopusbiopharma.com) today announced that permission has been granted by the U.S. Department of Defense to initiate a Hepatitis C efficacy and safety human clinical Phase II trial, testing the patented antiviral drug CB5300.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES